Formulation and preclinical evaluation of a Toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator

The toll-like receptor 7 and 8 (TLR7/8) agonist Resiquimod (R848) has been recognized as a promising immunostimulator for the treatment of cutaneous cancers in multiple clinical trials. However, systemic administration of R848 often results in strong immune-related toxicities while having limited th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Control Release
Hauptverfasser: Lu, Ruolin, Groer, Chad, Kleindl, Peter A., Moulder, K. Ryan, Huang, Aric, Hunt, Jordan R., Cai, Shuang, Aires, Daniel J., Berkland, Cory, Forrest, Laird
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6679596/
https://ncbi.nlm.nih.gov/pubmed/31173789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2019.06.003
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge